Biotime Inc (BTX) 4.07 $BTX
Asterias Biotherapeutics Completes Public Offering and Private Placement of Common Stock
PR Newswire - Tue Feb 10, 2:00PM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"
, a leading biotechnology company in the emerging field of regenerative medicine, announced today that it has completed the previously announced underwritten public offering and concurrent private placement of its common stock.
BTX: 4.07 (+0.05), AST: 3.85 (+0.13)
OncoCyte to Present Cancer Diagnostic Clinical Study Data at AACR Annual Meeting
Business Wire - Fri Feb 06, 8:00AM CST
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that two abstracts, summarizing clinical studies of OncoCyte's PanC-Dx(TM) diagnostic products for bladder and breast cancer, have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 in Philadelphia. PanC-Dx(TM) is a class of non-invasive cancer diagnostics based on OncoCyte's proprietary set of cancer markers, which were discovered by company scientists through an analysis of broad gene expression patterns in numerous cancer types. These markers are the subject of multiple pending patent claims filed in numerous countries worldwide and are owned by OncoCyte.
BTX: 4.07 (+0.05)
Asterias Biotherapeutics Prices Public Offering of Common Stock
PR Newswire - Thu Feb 05, 9:37AM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company" , a leading biotechnology company in the emerging field of regenerative medicine, today announced today that it has priced an underwritten public offering of its common stock at a price of $3.90 per share. Concurrently, the Company entered into a private placement for the sale of common stock at the same price as the underwritten public offering.
BTX: 4.07 (+0.05), AST: 3.85 (+0.13)
Asterias Biotherapeutics Announces Public Offering of Common Stock
PR Newswire - Wed Feb 04, 3:33PM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company" , a leading biotechnology company in the emerging field of regenerative medicine, today announced that it has commenced an underwritten public offering of its common stock. MLV & Co. LLC is acting as the Sole Book-Running Manager for the offering.
BTX: 4.07 (+0.05), AST: 3.85 (+0.13)
BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy
Business Wire - Mon Jan 26, 7:01AM CST
BioTime, Inc. (NYSE MKT: BTX) announced today the issuance of 14 new patents covering a wide range of the core technologies of BioTime and its subsidiaries Asterias Biotherapeutics, Inc. (NYSE MKT: AST), OrthoCyte Corporation, ES Cell International Pte Ltd, OncoCyte Corporation, and ReCyte Therapeutics, Inc. The new patents issued over Q3 and Q4 of 2014 add to the BioTime family of companies' patent estate of over 600 patents and patent applications pending worldwide, which is the largest known patent estate in the field of pluripotent stem cell technology for human therapeutic application, an emerging field known as "regenerative medicine."
BTX: 4.07 (+0.05), AST: 3.85 (+0.13)
BioTime, Inc.: Following The Smart Money
JMY Investments - at Seeking Alpha - Mon Jan 26, 7:00AM CST
BTX: 4.07 (+0.05)
BioTime Subsidiary OncoCyte Corporation Appoints William Annett to Its Board of Directors
Business Wire - Mon Jan 12, 7:02AM CST
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that William Annett has been appointed to OncoCyte's Board of Directors. Mr. Annett has extensive experience within the biotechnology and diagnostics industry, having held the position of Chief Executive Officer at six organizations as well as having experience in senior management positions at Genentech, Accenture and other companies. Mr. Annett holds an M.B.A. from the Harvard Business School.
BTX: 4.07 (+0.05)
The Small-Cap Stock I'm Watching in 2015
Motley Fool Staff - Motley Fool - Wed Jan 07, 9:00AM CST
Small-cap stocks can offer investors impressive gains, but they also come with their fair share of risk. That makes it particularly important to research small-cap companies before putting them in your portfolio. However, knowing which small caps to...
JNJ: 99.62 (+1.18), ENPH: 15.15 (+0.37), GERN: 3.03 (unch), BTX: 4.07 (+0.05), OPHT: 51.11 (+0.12)
New operating chief at BioTime
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 8:12AM CST
BTX: 4.07 (+0.05)
BioTime Appoints Adi Mohanty Chief Operating Officer
Business Wire - Mon Dec 29, 7:30AM CST
BioTime, Inc. (NYSE MKT:BTX), a leader in developing pluripotent stem-cell therapies and other technologies designed to address major unmet medical needs, today announced the appointment of Adi Mohanty to the position of Chief Operating Officer of the Company. Mr. Mohanty's primary responsibilities will be to build BioTime's business through the development of its subsidiaries and through the further development and commercialization of BioTime's HyStem(R)-based products. Mr. Mohanty will report to Michael D. West, Ph.D., BioTime's Chief Executive Officer.
BTX: 4.07 (+0.05)
BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of Cell Assays for Drug Testing
Business Wire - Mon Dec 15, 11:00AM CST
BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary ES Cell International Pte. Ltd. ("ESI" and GE Healthcare (GEHC) have signed a set of license agreements through which GEHC received rights to ESI's stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discovery and toxicity screening. In addition, the agreements give GEHC the right to grant sub-licenses to the ESI patent portfolio and, in certain circumstances, ESI may further sublicense its rights for the purpose of marketing stem cell-derived products. Financial terms were not disclosed.
BTX: 4.07 (+0.05)
BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of Urine-Based Bladder Cancer Diagnostic
Business Wire - Mon Dec 15, 10:00AM CST
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test. The study, which involved 100 patients, was conducted in collaboration with investigators in the Department of Pathology, Division of Cytopathology, at a leading medical institution with an international reputation for excellence and discovery. Initial results of the study have been submitted for presentation at a large upcoming cancer society meeting; eventual publication of the final results in a peer-reviewed clinical journal is also anticipated.
BTX: 4.07 (+0.05)
BioTime Appoints Angus C. Russell to Board of Directors
Business Wire - Mon Dec 15, 7:38AM CST
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Angus C. Russell, former Chief Executive Officer of Shire plc, has been appointed to BioTime's Board of Directors.
SHPG: 239.82 (+6.11), ITMN: 73.89 (-0.02), BTX: 4.07 (+0.05)
BioTime investor day approaches
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 2:29PM CST
BTX: 4.07 (+0.05)
BioTime to Host Investor and Analyst Day on December 15, 2014
Business Wire - Fri Dec 12, 1:30PM CST
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced today that it will host its Investor and Analyst Day meeting on Monday, December 15, 2014 at the Harvard Club of New York City. A live webcast of the presentations will begin at 1:15 pm ET and the webcast will conclude by 4:00 pm ET.
BTX: 4.07 (+0.05), AST: 3.85 (+0.13)
Commit To Purchase BioTime At $2.50, Earn 14.5% Annualized Using Options
at The Street - Tue Dec 09, 10:34AM CST
Investors considering a purchase of BioTime, Inc. shares, but tentative about paying the going market price of $3.26/share, might benefit from considering selling puts among the alternative strategies at their disposal.
BTX: 4.07 (+0.05)
BioTime to Present at the LD Micro VII Conference
Business Wire - Wed Dec 03, 7:30PM CST
BioTime, Inc. (NYSE MKT:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the LD Micro VII Conference taking place December 2-4, 2014 in Los Angeles, California.
BTX: 4.07 (+0.05)
BioTime Harnesses Geron's Stem Cell Technology And Its Founder; Is That Enough To Survive The Biotech Revolution?
Ian C. Clift - Seeking Alpha - Wed Dec 03, 9:51AM CST
As a typical contrarian, I like to look for undervalued stocks and buy them up. As such, I have a long-term investment in Geron (NASDAQ: GERN ), which played out well with the recent news of an exclusive deal for Imetelstat inked with Johnson &...
JNJ: 99.62 (+1.18), GERN: 3.03 (unch), BTX: 4.07 (+0.05), AST: 3.85 (+0.13), TEVA: 56.77 (-0.58)
A Timely Interview With BioTime's CEO And His Chief Commercial Officer
JMY Investments - at Seeking Alpha - Mon Nov 17, 10:39AM CST
BTX: 4.07 (+0.05), STEM: 1.09 (-0.01)
Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results
PR Newswire - Mon Nov 10, 3:01PM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2014.
BTX: 4.07 (+0.05), AST: 3.85 (+0.13)
Asterias Biotherapeutics Completes Public Offering and Private Placement of Common Stock
PR Newswire - Tue Feb 10, 2:00PM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"
, a leading biotechnology company in the emerging field of regenerative medicine, announced today that it has completed the previously announced underwritten public offering and concurrent private placement of its common stock. BTX: 4.07 (+0.05), AST: 3.85 (+0.13)
OncoCyte to Present Cancer Diagnostic Clinical Study Data at AACR Annual Meeting
Business Wire - Fri Feb 06, 8:00AM CST
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that two abstracts, summarizing clinical studies of OncoCyte's PanC-Dx(TM) diagnostic products for bladder and breast cancer, have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 in Philadelphia. PanC-Dx(TM) is a class of non-invasive cancer diagnostics based on OncoCyte's proprietary set of cancer markers, which were discovered by company scientists through an analysis of broad gene expression patterns in numerous cancer types. These markers are the subject of multiple pending patent claims filed in numerous countries worldwide and are owned by OncoCyte.
BTX: 4.07 (+0.05)
Asterias Biotherapeutics Prices Public Offering of Common Stock
PR Newswire - Thu Feb 05, 9:37AM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"
, a leading biotechnology company in the emerging field of regenerative medicine, today announced today that it has priced an underwritten public offering of its common stock at a price of $3.90 per share. Concurrently, the Company entered into a private placement for the sale of common stock at the same price as the underwritten public offering. BTX: 4.07 (+0.05), AST: 3.85 (+0.13)
Asterias Biotherapeutics Announces Public Offering of Common Stock
PR Newswire - Wed Feb 04, 3:33PM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"
, a leading biotechnology company in the emerging field of regenerative medicine, today announced that it has commenced an underwritten public offering of its common stock. MLV & Co. LLC is acting as the Sole Book-Running Manager for the offering. BTX: 4.07 (+0.05), AST: 3.85 (+0.13)
BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy
Business Wire - Mon Jan 26, 7:01AM CST
BioTime, Inc. (NYSE MKT: BTX) announced today the issuance of 14 new patents covering a wide range of the core technologies of BioTime and its subsidiaries Asterias Biotherapeutics, Inc. (NYSE MKT: AST), OrthoCyte Corporation, ES Cell International Pte Ltd, OncoCyte Corporation, and ReCyte Therapeutics, Inc. The new patents issued over Q3 and Q4 of 2014 add to the BioTime family of companies' patent estate of over 600 patents and patent applications pending worldwide, which is the largest known patent estate in the field of pluripotent stem cell technology for human therapeutic application, an emerging field known as "regenerative medicine."
BTX: 4.07 (+0.05), AST: 3.85 (+0.13)
BioTime, Inc.: Following The Smart Money
JMY Investments - at Seeking Alpha - Mon Jan 26, 7:00AM CST
BTX: 4.07 (+0.05)
BioTime Subsidiary OncoCyte Corporation Appoints William Annett to Its Board of Directors
Business Wire - Mon Jan 12, 7:02AM CST
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that William Annett has been appointed to OncoCyte's Board of Directors. Mr. Annett has extensive experience within the biotechnology and diagnostics industry, having held the position of Chief Executive Officer at six organizations as well as having experience in senior management positions at Genentech, Accenture and other companies. Mr. Annett holds an M.B.A. from the Harvard Business School.
BTX: 4.07 (+0.05)
The Small-Cap Stock I'm Watching in 2015
Motley Fool Staff - Motley Fool - Wed Jan 07, 9:00AM CST
Small-cap stocks can offer investors impressive gains, but they also come with their fair share of risk. That makes it particularly important to research small-cap companies before putting them in your portfolio. However, knowing which small caps to...
JNJ: 99.62 (+1.18), ENPH: 15.15 (+0.37), GERN: 3.03 (unch), BTX: 4.07 (+0.05), OPHT: 51.11 (+0.12)
New operating chief at BioTime
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 8:12AM CST
BTX: 4.07 (+0.05)
BioTime Appoints Adi Mohanty Chief Operating Officer
Business Wire - Mon Dec 29, 7:30AM CST
BioTime, Inc. (NYSE MKT:BTX), a leader in developing pluripotent stem-cell therapies and other technologies designed to address major unmet medical needs, today announced the appointment of Adi Mohanty to the position of Chief Operating Officer of the Company. Mr. Mohanty's primary responsibilities will be to build BioTime's business through the development of its subsidiaries and through the further development and commercialization of BioTime's HyStem(R)-based products. Mr. Mohanty will report to Michael D. West, Ph.D., BioTime's Chief Executive Officer.
BTX: 4.07 (+0.05)
BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of Cell Assays for Drug Testing
Business Wire - Mon Dec 15, 11:00AM CST
BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary ES Cell International Pte. Ltd. ("ESI"
and GE Healthcare (GEHC) have signed a set of license agreements through which GEHC received rights to ESI's stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discovery and toxicity screening. In addition, the agreements give GEHC the right to grant sub-licenses to the ESI patent portfolio and, in certain circumstances, ESI may further sublicense its rights for the purpose of marketing stem cell-derived products. Financial terms were not disclosed. BTX: 4.07 (+0.05)
BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of Urine-Based Bladder Cancer Diagnostic
Business Wire - Mon Dec 15, 10:00AM CST
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test. The study, which involved 100 patients, was conducted in collaboration with investigators in the Department of Pathology, Division of Cytopathology, at a leading medical institution with an international reputation for excellence and discovery. Initial results of the study have been submitted for presentation at a large upcoming cancer society meeting; eventual publication of the final results in a peer-reviewed clinical journal is also anticipated.
BTX: 4.07 (+0.05)
BioTime Appoints Angus C. Russell to Board of Directors
Business Wire - Mon Dec 15, 7:38AM CST
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Angus C. Russell, former Chief Executive Officer of Shire plc, has been appointed to BioTime's Board of Directors.
SHPG: 239.82 (+6.11), ITMN: 73.89 (-0.02), BTX: 4.07 (+0.05)
BioTime investor day approaches
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 2:29PM CST
BTX: 4.07 (+0.05)
BioTime to Host Investor and Analyst Day on December 15, 2014
Business Wire - Fri Dec 12, 1:30PM CST
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced today that it will host its Investor and Analyst Day meeting on Monday, December 15, 2014 at the Harvard Club of New York City. A live webcast of the presentations will begin at 1:15 pm ET and the webcast will conclude by 4:00 pm ET.
BTX: 4.07 (+0.05), AST: 3.85 (+0.13)
Commit To Purchase BioTime At $2.50, Earn 14.5% Annualized Using Options
at The Street - Tue Dec 09, 10:34AM CST
Investors considering a purchase of BioTime, Inc. shares, but tentative about paying the going market price of $3.26/share, might benefit from considering selling puts among the alternative strategies at their disposal.
BTX: 4.07 (+0.05)
BioTime to Present at the LD Micro VII Conference
Business Wire - Wed Dec 03, 7:30PM CST
BioTime, Inc. (NYSE MKT:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the LD Micro VII Conference taking place December 2-4, 2014 in Los Angeles, California.
BTX: 4.07 (+0.05)
BioTime Harnesses Geron's Stem Cell Technology And Its Founder; Is That Enough To Survive The Biotech Revolution?
Ian C. Clift - Seeking Alpha - Wed Dec 03, 9:51AM CST
As a typical contrarian, I like to look for undervalued stocks and buy them up. As such, I have a long-term investment in Geron (NASDAQ: GERN ), which played out well with the recent news of an exclusive deal for Imetelstat inked with Johnson &...
JNJ: 99.62 (+1.18), GERN: 3.03 (unch), BTX: 4.07 (+0.05), AST: 3.85 (+0.13), TEVA: 56.77 (-0.58)
A Timely Interview With BioTime's CEO And His Chief Commercial Officer
JMY Investments - at Seeking Alpha - Mon Nov 17, 10:39AM CST
BTX: 4.07 (+0.05), STEM: 1.09 (-0.01)
Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results
PR Newswire - Mon Nov 10, 3:01PM CST
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2014.
BTX: 4.07 (+0.05), AST: 3.85 (+0.13)
